Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;64(10):2992-3000.
doi: 10.1007/s10620-019-05614-6. Epub 2019 Apr 13.

Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B

Hae Lim Lee  1 , Jeong Won Jang  2 , Ji Won Han  3 , Sung Won Lee  1 , Si Hyun Bae  1 , Jong Young Choi  1 , Nam Ik Han  1 , Seung Kew Yoon  1 , Hee-Je Kim  4 , Seok Lee  4 , Seok-Goo Cho  4 , Chang-Ki Min  4 , Dong-Wook Kim  4 , Jong Wook Lee  4
Affiliations

Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B

Hae Lim Lee et al. Dig Dis Sci. 2019 Oct.

Abstract

Background and aims: Long-term results on hepatitis B virus (HBV) reactivation in patients with resolved infection during anti-cancer therapy are unknown. This study investigated long-term risk and therapeutic endpoints including hepatitis B surface antigen (HBsAg) seroclearance following antiviral therapy in patients developing reactivation of resolved HBV.

Methods: The study included 528 consecutive HBsAg-negative/hepatitis B core antibody-positive patients who underwent rituximab treatment or hematopoietic stem cell transplantation (HSCT) between 2006 and 2016. Long-term outcomes of patients with reactivation after antiviral therapy were examined in comparison with 37 HBsAg-positive chronic carriers under the same medical settings.

Results: The 7-year cumulative rate of HBV reactivation was 10.8% and 57.9% in patients receiving rituximab treatment and HSCT, respectively. After antiviral initiation, patients with reactivation of resolved HBV showed significantly higher 1-year cumulative rates of hepatitis B e antigen seroconversion (69.2% vs. 22.6%, P = 0.008) and HBsAg seroclearance (61.8% vs. 3.3%, P < 0.001) than chronic HBsAg carriers. Reactivation of resolved HBV was independently predictive of HBsAg seroclearance in a combined group of reactivated patients and chronic HBsAg carriers. Low viral load at reactivation was predictive of HBsAg seroclearance in reactivated patients. The majority of patients with HBsAg seroclearance developed anti-HBs. None of the reactivated patients who achieved HBsAg seroclearance relapsed after cessation of antiviral therapy.

Conclusions: HBsAg seroclearance rapidly occurs following antiviral therapy for reactivation of resolved HBV infection, suggesting distinct clinical phenotypes as well as shorter duration of HBV infection associated with this particular disease setting-HBV reactivation.

Keywords: Antiviral therapy; HBV reactivation; HBsAg seroclearance; Resolved hepatitis B.

PubMed Disclaimer

References

    1. Gastroenterology. 2006 Jul;131(1):59-68 - PubMed
    1. J Hepatol. 2008 Feb;48(2):380-1 - PubMed
    1. J Clin Oncol. 2009 Feb 1;27(4):605-11 - PubMed
    1. J Biomed Sci. 2009 Apr 20;16:41 - PubMed
    1. Hepatology. 2010 Feb;51(2):422-30 - PubMed

Publication types

MeSH terms

LinkOut - more resources